Assessment of Efficacy and Safety of COVID-19 Vaccination in Cancer Patients of Pakistan /
Sadaf Ishaq
- 58p. Soft Copy 30cm
Protection through a thorough vaccination campaign has become crucial with the beginning of the second wave of COVID-19 infection globally, notably in Pakistan in March-April 2021. The effectiveness of vaccines in lowering the chance of contracting serious illnesses makes them essential weapons in the fight against COVID-19. According to the GLOBOCAN database, approximately, 19.3 million new cases in 2020 of cancer were recorded. which made it difficult for medical practitioners to safeguard so many "sensitive" people against COVID-19. The COVID-19 outbreak could only be stopped after it had begun through vaccination. Around the world, there is doubt regarding the effectiveness and safety of the current COVID-19 immunization. Investigating the adverse consequences of post-COVID-19 vaccination is the goal of this study, in cancer and non-cancer subjects who received a range of vaccinations, including inactivated viral vaccines (Sinopharm and Sinovac), RNAbased vaccines (Moderna and Pfizer), and non-replicating viral vaccines (AstraZeneca and Casino bio) based on Adenovirus (Sputnik-V). In this study, questionnaires and interviews were used to examine the concurrent side effects of various COVID-19 vaccines in populations with and without cancer. IBM-SPSS was used to analyze the data using a chi-square test and an independent sample T-test. The non-cancer category was where the majority of the negative effects were documented. Patients who received the vaccine safely under the care of the medical oncology clinic reported no significant toxicity. Concluded that these vaccines are safe for both cancer patients and people without cancer. Based on the information available, we advise cancer patients to get the inactivated viral-based COVID-19 vaccination